Corvus Pharma rises as FDA backs blood cancer drug study

Corvus Pharmaceuticals

06/09/2023 22:06

** Shares of drug developer Corvus Pharmaceuticals  CRVS.O 
rise 8% to $2.26 after the bell   
    ** Co says the U.S. FDA has confirmed the study design for a
late-stage trial testing its experimental drug to treat a type
of blood cancer 
    ** CRVS plans to initiate the registrational trial for the
drug candidate, soquelitinib, in Q1 2024 
    ** Soquelitinib is being tested to treat relapsed peripheral
T cell lymphoma (PTCL) 
    ** PTCL is a diverse group of aggressive lymphomas that
develop from mature-stage white blood cells called T-cells 
    ** Up to last close, stock has more than doubled YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))